30 closest matches · ranked by relevance
Pharmacokinetics of Mirabegron · Food Effect · Healthy Chinese Subjects
Primary: Area Under The Concentration-Time Curve (AUC) From The Time of Dosing Extrapolated to Time Infinity (AUCinf) For Mirabegron — 81.8; 143; 263; 429 Hour*nanogram per…
Parkinson Disease · Overactive Bladder · Impaired Cognition
Primary: Change in Montreal Cognitive Assessment Total Score — 1.5; 2 units on a scale
Overactive Bladder
Primary: Change From Baseline to End of Treatment (EoT) in Mean Number of Micturitions Per 24 Hours — -0.90; -1.35 micturitions — p=<0.001
Neurogenic Detrusor Overactivity
Primary: Change From Baseline in Maximum Cystometric Capacity (MCC) at Week 24 — 72.09; 113.21 mL — p=<0.001
Overactive Bladder (OAB)
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 131; 135; 133; 120 Participants
Urologic Diseases · Urinary Bladder, Overactive · Urinary Bladder Diseases
Primary: Change From Baseline to Final Visit in the Mean Number of Micturitions Per 24 Hours — -2.95; -3.13 micturitions — p=0.15
Benign Prostatic Hyperplasia · Overactive Bladder
Primary: Change From Baseline to End of Treatment (EoT) in Mean Number of Micturitions Per Day — -2.00; -1.62 micturitions per day — p=0.039
Urinary Bladder, Overactive
Primary: Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 Hours — -0.96; -1.36; -1.38 Incontinence episodes — p=0.005
Urinary Bladder, Overactive
Primary: Number of Participants With and Severity of Treatment-emergent Adverse Events (TEAEs) — 222; 240; 251; 212 participants
Lower Urinary Tract Symptoms · Bladder Outlet Obstruction
Primary: Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax) — -0.33; 0.07; 0.30 mL/sec
Overactive Bladder
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 23; 21; 42; 69 Participants
Urinary Bladder, Overactive
Primary: Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 Hours — -1.13; -1.47; -1.63 Incontinence episodes — p=0.026
Overactive Bladder (OAB)
Primary: Participants Tolerability Assessed by the Medication Tolerability Scale of the Overactive Bladder-Satisfaction (OAB-S) Questionnaire at the End of Treatment (EOT)…
Urinary Bladder, Overactive
Primary: Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 Hours — -1.17; -1.57; -1.46; -1.27 Incontinence episodes — p=0.003
Overactive Bladder (OAB)
Primary: Change From Baseline to End of Treatment (EOT) in Mean Number of Micturitions Per 24 Hours — -1.7; -2.3 micturitions/24 hours — p=<0.001
Urge Incontinence · Overactive Bladder (OAB)
Primary: Change From Baseline (CFB) to the End of 12-Week Treatment Period in Mean Number of Micturition/24 Hours in Mirabegron 50 mg Group — -3.76 micturitions per 24 hours…
Resting Energy Expenditure · Thermogenesis · Brown Adipose Tissue
Primary: Cumulative Resting Energy Expenditure — 456.4; 494.7; 481.3; 492.8 kcal
Urologic Diseases · Urinary Bladder Diseases · Urological Manifestations
Primary: Change From Baseline to End of Treatment (EOT) in Mean Volume Voided Per Micturition — 14.0; 24.9; 34.5; 36.4 mL — p=0.97
Resting Energy Expenditure · Thermogenesis · Brown Adipose Tissue
Primary: Cold Temperature Deflection Point — 22.8; 22.97 degrees Celsius
Urinary Bladder Diseases · Urinary Bladder Overactive · Urologic Diseases
Primary: Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours — -1.8; -1.53; -1.67 incontinence episodes — p==0.001
Erectile Dysfunction · Overactive Bladder · Urinary Incontinence
Primary: Erectile Function Assessed by IIEF Questionnaire — 12.7 score on a scale
Overactive Bladder
Primary: Area Under the Concentration-time Curve From 0 to Infinity (AUC0-∞) After a Single Oral Dose of Vibegron 100 mg — 6337.17; 7137.53; 5156.07; 3466.04 nM•hr
Overactive Bladder
Primary: Response to Therapy — 15; 29 Participants
Overactive Bladder · Urinary Incontinence
Primary: Improved Overactive Bladder Symptoms as a Measure of Efficacy of Mirabegron — 13; 14; 25; 6 Participants
Urinary Bladder Overactive · Urinary Bladder Diseases\Urologic Diseases · Overactive Bladder
Primary: Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours — -1.34; -1.70; -1.76; -1.79 incontinence episodes — p=0.072
Overactive Bladder · Urinary Incontinence
Primary: Response to Urinary Incontinence as a Composite Measure of Efficacy of add-on Mirabegron — 12; 23 Participants
Urinary Bladder Overactive · Overactive Bladder · Urgency Incontinence
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 126; 134; 596; 61 Participants
Urge Incontinence · Urinary Incontinence, Urge
Primary: The Number of Participants Who Completed and Discontinued the Study — 11; 10; 1; 1 Participants — p=0.949
Renal Insufficiency
Primary: The Steady State Area Under the Drug Concentration Time Curve From 0 to 12 Hours Post Dose AUC(0-12). — 157.8; 276.5; 415.3 hour*nanogram/milliliter
Transplantation
Primary: Maximum Observed Serum Concentration (Cmax) of Belatacept — 3.9; 6.2; 8.5; 11.1 ug/mL